Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics, Inc. (KROS) reported Q1 2020 financial results and business updates. The company experienced a net loss of $11.9 million, up from $3.2 million in Q1 2019, attributed to R&D and public company transition costs. They completed a Series C financing raising $56 million in March and an IPO generating $110.4 million in April, providing a cash balance of $54.5 million as of March 31, 2020, expected to sustain operations into H2 2022. Progress continues with KER-047 and KER-050, and a Phase 2 trial for KER-050 is set for H2 2020, pending COVID-19 impacts.
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced four abstracts showcasing data from its KER-050 and ALK2 hematology programs at the virtual 25th Annual Congress of the European Hematology Association (EHA) from June 11-14, 2020. Key presentations include details on KER-050's effects on hemoglobin and platelet increases, red blood cell production in cynomolgus monkeys, and its potential for treating ineffective erythropoiesis. The company plans to commence Phase 2 trials for KER-050 in patients with myelodysplastic syndromes and myelofibrosis later this year.